Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efmody vs immediate-release hydrocortisone in Addison’s disease
2023-503584-42-00Phase 2Completed
- Sponsor
- RCSI University of Medicine and Health Sciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydrocortisone in Addison's disease (2 arms), sponsored by RCSI University of Medicine and Health Sciences. Primary endpoint: Change from baseline in AddiQoL after 11 weeks of Efmody vs immediate-release hydrocortisone. Started Jul 2023; status: completed.
02
Drugs
hydrocortisone
03
Conditions
Addison's disease
Beyond the preview
Go deeper on 2023-503584-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503584-42-00.